Showing 2291-2300 of 2527 results for "".
- Bausch Health Licenses Clearside Biomedical’s Xipere, An Investigational Treatment For Macular Edema Associated With Uveitishttps://modernod.com/news/bausch-health-licenses-clearside-biomedicals-xipere-an-investigational-treatment-for-macular-edema-associated-with-uveitis/2477035/Bausch Health Companies announced that an affiliate of Bausch Health has acquired an exclusive license for the commercialization and development of Xipere (triamcinolone acetonide suprachoroidal injectable suspension) in the United States and
- Wolfgang Haigis—Scientist Known for His Formulae—Dies at 72https://modernod.com/news/wolfgang-haigis-scientist-known-for-his-formulae-dies-at-72/2477025/The German Society for Cataract and Refractive Surgery (DGII) has announced that Prof. Dr. Wolfgang Haigis, a physicist working at the University of Wurzburg, died on October 15 at the age of 72. Dr. Haigis was a pioneer and a driving force in the development and the refinement of biometry
- Sun Pharma Launches Cequa for the Treatment of Dry Eye Disease in the UShttps://modernod.com/news/sun-pharma-launches-cequa-for-the-treatment-of-dry-eye-disease-in-the-us/2477008/Sun Pharmaceutical announced that its dry eye drug Cequa (cyclosporine ophthalmic solution) 0.09% is now commercially available the United States. Cequa, which offers the highest concentration of cyclosporine for ophthalmic use approved by the FDA, is indicated to increase tear production in pati
- Antibody-based eye drops show promise for treating dry eye diseasehttps://modernod.com/news/antibody-based-eye-drops-show-promise-for-treating-dry-eye-disease/2477005/Researchers at the University of Illinois at Chicago are the first to identify the presence of a specific type of antibody, called anti-citrullinated protein autoantibodies, or ACPAs, in human tear fluid. They are also the first to demonstrate that patients with dry eye d
- eSight 3 Approved on the US Department of Veterans Affairs (VA) Federal Supply Schedulehttps://modernod.com/news/esight-3-approved-on-the-us-department-of-veterans-affairs-va-federal-supply-schedule/2476985/eSight announced the approval of eSight 3–advanced sight-enhancing glasses for those living with visual impairments–on the United States Department of Veterans Affairs (VA) Federal Supply Schedule (FSS). The registration allows eSight to be included on the FSS through December 2023.<
- On World Sight Day, Allergan Launches National Campaign to Raise Awareness of Glaucomahttps://modernod.com/news/on-world-sight-day-allergan-launches-national-campaign-to-raise-awareness-of-glaucoma/2476984/Allergan announced a national education campaign called “My Glaucoma.” The campaign is designed to help people understand the burden of living with glaucoma and empower those with the disease and their caregivers to feel comfortable speaking with their doctor about a treatment
- Avedro Announces Schedule of Events at AAOhttps://modernod.com/news/avedro-announces-schedule-of-events-at-aao/2476970/Avedro announced its schedule of scientific and educational programs focused on corneal cross-linking and keratoconus during the American Academy of Ophthalmology annual meeting in San Francisco. Avedro’s presentations and educational events underscore the clinical community’s
- Johnson & Johnson Vision Launches Worldwide #ConnectedBySight Campaign in Honor of World Sight Dayhttps://modernod.com/news/johnson-johnson-vision-launches-worldwide-connectedbysight-campaign-in-honor-of-world-sight-day/2476949/In honor of World Sight Day on October 10, 2019, Johnson & Johnson Vision has launched a worldwide campaign to share the untold stories of eye care professionals, patients, and organizations who are inspiring the elevation of eye health as a global priority and demonstrating how the world is
- Oculis Announces Dosing of First Patient in Randomized Phase 2b (SKYGGN) Clinical Trial of OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgeryhttps://modernod.com/news/oculis-announces-dosing-of-first-patient-in-randomized-phase-2b-skyggn-clinical-trial-of-ocs-01-for-the-treatment-of-inflammation-and-pain-following-cataract-surgery/2476947/Oculis announced the dosing of the first patient in a phase 2b clinical trial evaluating the efficacy and safety of OCS-01 for the treatment of inflammation and pain following cataract surgery. OCS-01 is a unique topical formulation of dexamethasone based on the company’s proprietary
- Fight For Sight and Prevent Blindness Announce Call for Entries for the 2020 Joanne Angle Public Health Awardhttps://modernod.com/news/fight-for-sight-and-prevent-blindness-announce-call-for-entries-for-the-2020-joanne-angle-public-health-award/2476933/National non-profit organizations Fight for Sight and Prevent Blindness are announcing a call for applications for the Joanne Angle Public Health Award, a $25,000 grant to support a public health research project seeking to put an end to unnecessary vision loss. The award was named for Ms